Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (NRF-2022R1A4A1030421)
National Research Foundation of Korea (NRF-2020R1A2C3005834, RS-2024-00449612)
Korean Fund for Regenerative Medicine (KFRM24A0105L1)
- License Information
-
More Information
Article History
Received: 16 October 2024
Revised: 4 January 2025
Accepted: 21 January 2025
First Online: 25 February 2025
Declarations
:
: The authors declare the following competing financial interest(s): Dong Yun Lee declares a financial interest in Elixir Pharmatech Inc., and Kang Moo Huh declares a financial interest in Lab-to-Lab Co. Ltd. These companies did not support the aforementioned research and currently has no rights to any technology or intellectual property developed as part of this research. The rest of the authors declare no conflict of interest.
: The animal studies were performed after receiving approval of the Institutional Animal Care and Use Committee (IACUC) in Hanyang University (IACUC approval No. HY-IACUC-2016-0043A).
